Contact the Editorial Desk

Editorial correspondence

Saline Peptides welcomes correspondence about the research record: a citation quoted inaccurately, a clinical trial that has since published new results, a regulatory status update, or a peer-reviewed study on ipamorelin, MOTS-c, or retatrutide that should be added to the references page. This class of correction is the most useful message this desk receives, and each is read and considered carefully.

The most actionable submissions specify the page in question, the exact passage being corrected, and a supporting reference — a DOI or PubMed identifier wherever possible — so a proposed change can be verified against its source before it is acted on.

Editorial mailbox: editors@salinepeptides.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Saline Peptides is a literature digest, not a clinical service or a supplier, so it cannot advise on or recommend human use of any peptide discussed here, suggest a dose or administration schedule for any individual, evaluate whether a cited finding applies to a specific person's situation, or help locate, source, or recommend any compound from any supplier. Ipamorelin and MOTS-c are unapproved research chemicals; retatrutide is an investigational drug available only within registered clinical trials. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.